ClinicalTrials.gg
Not yet recruitingNCT07854769Updated Oct 2, 2026

Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer

An observational study in Non Small Cell Lung Cancer, sponsored by Fox Chase Cancer Center. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Fox Chase Cancer Center · Observational

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Carcinoma, Non-Small-Cell Lung by Fox Chase Cancer Center — 2 open to participants now, 4 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Fox Chase Cancer Center.

Started
2026
the only one that year
Observational
Only one
of the 22
Registered
22nd of 22
by date

Among the 22 studies in Carcinoma, Non-Small-Cell Lung by Fox Chase Cancer Center, this one is the only one that started in 2026, is the only observational one, and was the 22nd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 22 studies in Carcinoma, Non-Small-Cell Lung by Fox Chase Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Carcinoma, Non-Small-Cell Lung by Fox Chase Cancer Center, or all of them as a file.
02

Study summary

This observational study will evaluate whether a blood test can detect the return of non-small cell lung cancer at least three months before it is identified on routine imaging. The test measures circulating tumor DNA (ctDNA), which consists of small pieces of DNA released by cancer cells into the blood. Detecting ctDNA after treatment may indicate that cancer cells remain in the body, even when cancer is not visible on scans.

Approximately 200 adults with stage IB-IIIA non-small cell lung cancer who are considered candidates for surgery will participate at Fox Chase Cancer Center. Participants will receive standard-of-care treatment selected by their treating physicians, which may include chemotherapy and immunotherapy before or after surgery. Blood samples will be collected before treatment and at scheduled times during treatment and follow-up. Researchers will compare ctDNA results with routine imaging and clinical outcomes to assess how well the test predicts cancer recurrence.

Participants will be followed for up to five years after surgery, with the primary analysis focused on the first three years. Additional research in a subset of participants will examine blood, tissue, and stool samples to explore relationships among immune responses, gut bacteria, treatment response, and cancer recurrence.

Read the detailed description

This prospective, single-center observational cohort study will evaluate the clinical validity of a blood-based circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD) and predicting recurrence in patients with surgically resectable stage IB-IIIA non-small cell lung cancer (NSCLC), as defined by the American Joint Committee on Cancer (AJCC) 9th edition. Approximately 200 treatment-naïve adults who are considered surgical candidates by their treating physicians will be enrolled at Fox Chase Cancer Center over approximately two years.

Participants will receive standard-of-care treatment according to multidisciplinary tumor board recommendations and the treating physician's clinical judgment. Treatment pathways may include surgery followed by adjuvant therapy, neoadjuvant chemoimmunotherapy followed by surgery and adjuvant therapy, or neoadjuvant therapy followed by surgery and observation. The protocol does not assign anticancer treatment or specify the selection of therapeutic agents.

Tumor tissue and peripheral blood will be collected for MRD assessment. Tumor tissue will preferably be obtained before neoadjuvant treatment; surgical tissue may be used when a pretreatment specimen is unavailable or when participants proceed directly to surgery. Blood samples for ctDNA analysis will be collected at baseline and at protocol-specified treatment time points. A postoperative blood sample obtained four to six weeks after surgery will establish the landmark MRD assessment. Additional samples will be collected during and after adjuvant treatment, as applicable. During surveillance, MRD blood samples will be collected every three months for the first three years and every six months thereafter, for up to five years.

Clinical disease assessments will use standard-of-care computed tomography (CT) scans, radiology reports, and the treating physician's clinical assessment. Participants will be followed for up to five years after surgery or until radiographically confirmed disease progression, subject to protocol discontinuation criteria. Participants who initiate neoadjuvant therapy but do not undergo surgery will remain in follow-up, with blood collection continuing when feasible. Their available data will contribute to exploratory analyses, but they will not be evaluable for analyses requiring surgical pathology or the postoperative landmark assessment.

The primary objective is to determine the proportion of evaluable participants with documented recurrence in whom ctDNA predicts recurrence at least three months before clinical confirmation. The primary analysis will evaluate recurrence within 36 months after surgery. Secondary objectives include assessing the association between postoperative landmark ctDNA status and recurrence-free survival; determining the proportion of participants with negative ctDNA results at treatment entry; evaluating the sensitivity, specificity, positive predictive value, and negative predictive value of landmark ctDNA results for three-year recurrence; and measuring the interval between the first positive ctDNA result and clinically confirmed recurrence. Recurrence-free survival is defined as the time from the four-to-six-week postoperative ctDNA measurement to the first documented recurrence or death from any cause.

Exploratory analyses will examine longitudinal ctDNA patterns and associations with treatment pathways, clinicopathologic characteristics, genomic alterations, and recurrence. In the first 50 participants receiving neoadjuvant therapy, additional blood, surgical tumor or tumor-bed tissue, lymph node tissue, and stool samples will support correlative studies. These studies will evaluate immune cell profiles, T-cell clonotype dynamics, and gut microbiome characteristics in relation to pathologic response, MRD status, and disease recurrence.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • Non-small cell lung cancer
  • NSCLC
  • ctDNA
  • Circulating tumor DNA
  • Liquid biopsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older with treatment-naïve, histologically or cytologically confirmed stage IB-IIIA non-small cell lung cancer (AJCC 9th edition) who are considered candidates for surgical resection by their treating physicians. Approximately 200 participants will be enrolled at Fox Chase Cancer Center. Participants will receive standard-of-care treatment, which may include neoadjuvant therapy, surgery, and adjuvant therapy, as clinically indicated. Enrollment includes surgical candidates regardless of whether neoadjuvant therapy is planned.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have or cytologically confirmed stage 1B-3A (AJCC 9th edition) non-small cell lung carcinoma regardless of histology.
  • Patients must be treatment-naïve.
  • Patients must be deemed to be surgical candidates as assessed by their treating physician.
  • Age ≥ 18 years.
  • Ability to understand and willingness to sign a written and HIPAA consent document
  • Must be willing and able to provide a core tumor .

    1. A core tumor biopsy meeting minimum preanalytical requirements is necessary for MRD assay evaluation. The preference is for a sample prior to start of treatment as roughly 20% of patients will have a complete response and won't have any tumor in the surgical sample. However, if not possible, then sample could come after surgery.
    2. Patients who go directly to surgery could submit tumor samples after surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients with tumors are positive for EGFR exon 19 deletion or L858R mutation or ALK or ROS1 gene fusions are excluded.
  • Patients who at the discretion of investigators are not suitable for participation.
  • Patients must not be currently receiving any other agents or immunomodulatory agents with the exception of drugs used for treatment of rheumatoid arthritis or psoriasis
  • Patients with to chemotherapy or immunotherapy or refuse these treatments.
  • Patients who are unable/refuse to participate in blood collection at designated time points.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients With Surgically Resectable Stage IB-IIIA NSCLC

    Adults with treatment-naïve, histologically or cytologically confirmed stage IB-IIIA non-small cell lung cancer (AJCC 9th edition) who are considered surgical candidates by their treating physicians. Participants receive standard-of-care treatment, which may include neoadjuvant therapy, surgery, and adjuvant therapy, as clinically indicated. Serial blood samples and tumor tissue are collected for circulating tumor DNA and molecular residual disease analyses, with follow-up for cancer recurrence for up to five years after surgery. The first 50 participants receiving neoadjuvant therapy undergo additional blood, tissue, and stool collection for correlative studies.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With ctDNA Detection at Least Three Months Before Clinically Confirmed Recurrence

    Proportion of evaluable participants with documented lung cancer recurrence within 36 months after surgery who have a positive circulating tumor DNA (ctDNA) result at least three months before clinically confirmed recurrence. Recurrence is determined using standard-of-care imaging. The primary analysis includes participants with at least three months of follow-up and at least one evaluable ctDNA result obtained at or after the four-to-six-week postoperative assessment.

    Time frame: Up to 36 months after surgery.

Secondary outcomes

  1. Recurrence-Free Survival by Postoperative ctDNA Status

    Recurrence-free survival is measured from the ctDNA assessment performed four to six weeks after surgery to the first documented recurrence or death from any cause, whichever occurs first. Outcomes will be compared between participants with positive and negative ctDNA results at this postoperative landmark. Participants without an event will be censored at their last disease assessment.

    Time frame: From the four-to-six-week postoperative ctDNA assessment through up to five years after surgery.

  2. Proportion of Participants With Negative ctDNA Results at Treatment Entry

    Proportion of participants with a negative ctDNA result at entry into treatment. Treatment entry is defined as Cycle 1, Day 1 of neoadjuvant therapy for participants receiving neoadjuvant treatment, or the date of surgery for participants proceeding directly to surgical resection.

    Time frame: At treatment entry: Cycle 1, Day 1 of neoadjuvant therapy or the date of surgery.

  3. Sensitivity of Postoperative ctDNA for Predicting Three-Year Recurrence

    Proportion of participants who experience clinically confirmed recurrence within three years after surgery who have a positive ctDNA result at the four-to-six-week postoperative landmark assessment. The estimate will be reported with a 95% confidence interval.

    Time frame: ctDNA assessed four to six weeks after surgery; recurrence assessed through 36 months after surgery.

  4. Specificity of Postoperative ctDNA for Predicting Three-Year Recurrence

    Proportion of participants who do not experience clinically confirmed recurrence within three years after surgery who have a negative ctDNA result at the four-to-six-week postoperative landmark assessment. The estimate will be reported with a 95% confidence interval.

    Time frame: ctDNA assessed four to six weeks after surgery; recurrence assessed through 36 months after surgery.

  5. Positive Predictive Value of Postoperative ctDNA for Three-Year Recurrence

    Proportion of participants with a positive ctDNA result at the four-to-six-week postoperative landmark assessment who experience clinically confirmed recurrence within three years after surgery. The estimate will be reported with a 95% confidence interval.

    Time frame: ctDNA assessed four to six weeks after surgery; recurrence assessed through 36 months after surgery.

  6. Negative Predictive Value of Postoperative ctDNA for Three-Year Recurrence

    Proportion of participants with a negative ctDNA result at the four-to-six-week postoperative landmark assessment who do not experience clinically confirmed recurrence within three years after surgery. The estimate will be reported with a 95% confidence interval.

    Time frame: ctDNA assessed four to six weeks after surgery; recurrence assessed through 36 months after surgery.

  7. Time From First Positive ctDNA Result to Clinically Confirmed Recurrence

    Time interval, measured in months, between the first positive ctDNA result and clinically confirmed recurrence among participants with both events. The interval will be summarized using descriptive statistics. The number and proportion of participants with positive ctDNA results without subsequent recurrence, and those with recurrence without a positive ctDNA result, will also be reported.

    Time frame: Through up to five years after surgery.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2029, 35 months later.

Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 35 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Oct 6, 2026
Primary completionEst.
Oct 5, 2029
CompletionEst.
Oct 5, 2031
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854769
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 6, 2026 (estimated)
Primary completion
Oct 5, 2029 (estimated)
Completion
Oct 5, 2031 (estimated)
Last update
Oct 2, 2026

Study contacts

Hossein Borghaei, DO
Contact
hossein.borghaei@fccc.edu
215-728-4300
Henkel Valentine, PhD
Contact
protocoldev@fccc.edu
267-882-0820
Hossein Borghaei, DO
principal investigator · Fox Chase Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion